Re: some positive PR
If the promise of the drugs which are currently being investigated by IMGN can be realized, the public is in for some major improvements with their medicine. Takeda shelling out some big bucks to research IMGN's IGN technology indicative that they liked its potential. Not much info re: MLN6907 vs GCC. Bayer and Sanofi progressing with their R&D re: IMGN's maytansine platform.
and so we wait.
ASH will also have up-to-date bt062 data; here's excerpt of current abstract:
Thirteen of the evaluable BT062/Len/dex-treated patients had prior exposure to both Len and Bort and progressed on or within 60 days of their last therapy. ORR was 54% among these patients, including 1 complete response (CR), 4 very good partial responses (VGPR) and 2 PRs. Seventeen patients were treated with BT062/Pom/dex, all had prior exposure to both Len and Bort and progressed on or within 60 days of their last therapy. ORR was 79%, with 4 VGPR and 7 PR among the 14 patients evaluable for efficacy. Median PFS has not been reached after 7.5 months median follow up, with 7 patients still on treatment. Updated safety and activity data will be presented. Conclusion: BT062 has been found to be well tolerated when used in combination with Len/dex or Pom/dex, with encouraging activity even in patients with Len- and Bort-pretreated disease progressing on or within 60 days of completion of their last therapy.